Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
about
Impact of nausea and vomiting on quality of life in cancer patients during chemotherapyPalonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapyTreatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatmentCorticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer.Breast cancer (metastatic).Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy.The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.Control of nausea and vomiting after chemotherapy: what is the evidence?5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial.Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.Negative regulation of SEK1 signaling by serum- and glucocorticoid-inducible protein kinase 1.Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.Emerging drugs for chemotherapy-induced emesis.Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studiesThe neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy.Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary.Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivoPalonosetron: a second-generation 5-hydroxytryptamine receptor antagonist.Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetronRole of corticosteroids in palliative care.A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy.Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy.Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting.Chronic therapy with selective serotonin reuptake inhibitors and survival in newly diagnosed cancer patients.Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.Development and Validation of RP-HPLC Method for Simultaneous Determination of Granisetron and DexamethasoneChemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life.Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting.Use of antipsychotic medication in chemotherapy-induced nausea and vomiting.Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer.Delayed nausea and vomiting in children receiving antineoplastics.A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.Sample size determination and re-estimation for matched pair designs with multiple binary endpoints.2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.
P2860
Q24802757-D36297E1-E853-44CE-B905-0E32DBBEFE76Q26783229-326193E9-CD34-4734-ABFF-598AFF7927C6Q26784070-AE6B3F57-B862-4EE2-B280-E24DB4654053Q28269736-93DC65F9-14C0-418C-A82E-81505BE2B16AQ33235435-BB4B9ABD-6DA1-4468-82D2-C0878DBBC18BQ33448016-C730191E-153C-4D7C-9E09-76C1062DFC7EQ34121232-D535BEC0-BD6E-4A1A-B607-964B01147620Q34418467-6A319C6E-839D-42DA-8BA7-2D79DAE9156DQ34647257-B03B0325-EA24-4EC7-B834-B4A30BF4536BQ34773714-720BD0FD-C198-4EB7-89D7-D6BA2DDBBC77Q35146420-76689CAE-7AAB-4C77-A8AE-E1AA53817006Q35779340-F2FC9188-A139-4A2E-A3AA-62D019A24FB0Q35880610-B7623442-92E7-43FD-828D-858D84ABB6CAQ35918427-292D0EDF-F3BA-487B-A640-C1A93953955FQ35964412-277C2FEE-3B59-434A-9A07-2F6B7BF90455Q36064834-491FB99C-23D1-429C-B8E0-DCB533FA3B86Q36205615-3423E6D2-0242-4B79-B435-4FF690F64EECQ36407422-3B683EDB-C0BD-42C8-A8B0-23480BBBBD52Q36510919-5FDE4992-75A2-48CC-B9F1-CA7CCCCD8EBEQ36548740-573ABCF0-E1AC-4411-9F01-52DF4C0F170EQ36564254-5A1C3736-D7DC-4B11-AB38-DE843AB92469Q36616478-4A05FEBB-1626-4105-B5FE-9487CE8480DBQ36616499-6B900EE0-090F-4D67-A74C-20531A3CFA6BQ36891054-DD5A6888-C717-4F25-BBA4-DCB99545C668Q37010936-A3E8EFDC-C0F7-48F3-B059-9566326C7BDFQ37570350-D1A2757F-9565-4E3B-AF97-579E1F884EB9Q37606033-A90D9C34-FEA9-43CA-983E-B8B59BBF35E6Q37636028-2E38D254-EEFE-45CD-8F7A-A37E6C7998B5Q40143472-BF2B9A8B-02AC-424C-AD41-7C14CF9AFE90Q40311680-28E464F3-D591-4CB6-AEB3-6188DE45D36EQ41385767-4678C432-2BBF-42F7-B214-78A4E18960C2Q42406114-9D91CB8E-A2ED-4105-8968-224A0FD13D8AQ42642028-C9490B05-F382-4283-AAE5-C8EDAC8F9007Q42645757-CEF218E9-F0B0-4E5F-AF4F-9587CF52F047Q43265628-4F7E9C29-0651-4883-ABE1-E3C9ED6135BFQ43673718-0C8A3BAA-02D8-48ED-92BA-02347FF353C0Q43701963-6762DE08-9C66-47D9-8C5E-288C3BAC6EFAQ45114050-2962D549-F1AD-4251-8DE0-C4979F7C19A6Q45720845-AEBBD3F8-BFC7-49D8-9F32-B34EF7BE65C5Q46355232-2EFEAC7C-7171-4F2C-AA46-21F2B8F74103
P2860
Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Dexamethasone alone or in comb ...... iting induced by chemotherapy.
@ast
Dexamethasone alone or in comb ...... iting induced by chemotherapy.
@en
type
label
Dexamethasone alone or in comb ...... iting induced by chemotherapy.
@ast
Dexamethasone alone or in comb ...... iting induced by chemotherapy.
@en
prefLabel
Dexamethasone alone or in comb ...... iting induced by chemotherapy.
@ast
Dexamethasone alone or in comb ...... iting induced by chemotherapy.
@en
P1476
Dexamethasone alone or in comb ...... iting induced by chemotherapy.
@en
P2093
Italian Group for Antiemetic Research
P304
P356
10.1056/NEJM200005253422102
P407
P577
2000-05-01T00:00:00Z